No Data
HUA MEDICINE-B (02552): HUA MEDICINE Shanghai formally delivered a termination notice to Bayer according to the agreement.
HUA MEDICINE-B (02552) announced that on December 31, 2024, HUA MEDICINE in Shanghai will, according to the agreement, supply to Ba...
Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.
① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.
The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!
Industry pessimistic expectations may improve.
How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.
① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.
Hualing Pharmaceutical announced the successful completion of Phase I clinical trials for its second-generation glucokinase activator conducted in the usa.
Shanghai, November 30, 2024 /PRNewswire/ -- Hualing Pharmaceutical ("the company", Hong Kong Stock Exchange stock code: 2552.HK) today announced at the 9th China BioMed Innovation and Investment Conference (CBIIC) that it has successfully completed the Phase Ia clinical study of the second-generation glucose kinase activator (GKA) conducted in the USA. The Phase Ia clinical trial of the second-generation GKA (HM-002-1005) is
Hua Ling Pharmaceuticals announces the successful completion of the SENSITIZE study conducted in hong kong, china.
On November 30, 2024, shanghai /美通社/ -- china meheco group ("company", Stock code: 2552.HK on the Hong Kong Stock Exchange) announced today at the 9th China BioMed Innovation and Investment Conference (CBIIC) that the company has successfully completed the SENSITIZE research in collaboration with Professor Juliana Chan's team at the Chinese University of Hong Kong, aiming to improve β cell function using DPP-4 Inhibitors.
Is Hua Medicine (Shanghai) (HKG:2552) Using Debt In A Risky Way?
No Data
